

## Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in EGFR-Mutant Non-Small Cell Lung Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. The Phase III FLAURA2 trial evaluating osimertinib combined with chemotherapy versus osimertinib alone for patients with previously untreated, EGFR-mutated non-small cell lung cancer (NSCLC) reported which of the following efficacy outcomes with the combination?**

  - Inferior overall survival (OS) outcomes
  - A numerical but nonsignificant increase in OS
  - A significant increase in OS**
- 2. The Phase III MARIPOSA trial evaluating amivantamab and lazertinib versus osimertinib monotherapy in the front-line setting for patients with EGFR-mutant locally advanced or metastatic NSCLC reported which of the following efficacy outcomes for those receiving amivantamab and lazertinib?**

  - No significant difference in OS in high-risk subgroups
  - A statistically significant improvement in OS in the all-comers population**
  - A statistically significant improvement only in high-risk subgroups
  - Inferior OS outcomes in the all-comers population
- 3. Based on the results of the pooled analysis of the TROPION-Lung01 and TROPION-Lung05 trials, the FDA has granted accelerated approval to datopotamab deruxtecan in which of the following settings?**

  - Previously untreated EGFR-mutant NSCLC, excluding uncommon EGFR mutations and exon 20 insertions
  - Previously untreated EGFR-mutant NSCLC, including uncommon EGFR mutations and exon 20 insertions
  - EGFR-mutant lung cancers, excluding uncommon EGFR mutations and exon 20 insertions, after treatment with an EGFR tyrosine kinase inhibitor (TKI) and chemotherapy
  - EGFR-mutant lung cancers, including uncommon EGFR mutations and exon 20 insertions, after treatment with an EGFR TKI and chemotherapy**
- 4. Which of the following side effects represents a notable any-grade adverse event experienced by most patients receiving sacituzumab tirumotecan in the OptiTROP-Lung04 study?**

  - Hypokalemia
  - Diarrhea
  - Rash
  - Stomatitis**
- 5. The Phase IIb REZILIENT1 study evaluating ziplertinib for patients with previously treated advanced NSCLC and an EGFR exon 20 insertion reported which of the following confirmed objective response rates in the primary efficacy population?**

  - 22%
  - 35%**
  - 54%
  - 68%